Sacituzumab Govitecan — Drug Intelligence | 32 EU Trials

Filter these 32 trials by condition, phase, country and more.

Open in Search →

32 Registered trials

10 Recruiting

18 Completed trials

18 Sponsors

17 Countries

Phase III

Phase II

Phase III: 12 Phase II: 17 Phase I/II: 1 Phase IV: 2

Oversight events:

2 serious breaches 1 unexpected event across 3 trials

View oversight register →

Indications tested

Triple negative breast cancer 5 Breast cancer female 4 Non-small cell lung cancer 4 Breast cancer male 3 Bladder cancer 2 Breast cancer stage II 2 Breast cancer stage I 2 Breast cancer 2 Breast cancer stage III 1 Lung neoplasm malignant 1 Non-small cell lung cancer stage IIIA 1 Small cell lung cancer extensive stage 1

Sponsors using this IMP

Gilead Sciences Inc. 12 Medica Scientia Innovation Research S.L. 2 Ospedale San Raffaele S.r.l. 2 Unicancer 2 WSG Westdeutsche Studiengruppe GmbH 2 Academisch Ziekenhuis Maastricht 1 AIO-Studien gGmbH 1 Associacio Per A La Recerca Oncologica 1 Champalimaud Clinical Centre 1 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 1 Fondazione IRCCS Istituto Nazionale Dei Tumori 1 Fundacion GECP 1

All trials — page 2

32 total

A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Ended

2024-512148-50-00 Phase III 10 countries Gilead Sciences Inc.
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 Phase III 6 countries GBG Forschungs GmbH
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast… Ended

2023-505257-40-00 Phase I/II 2 countries Institut fuer Klinische Krebsforschung IKF GmbH
Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-N… Ended

2024-514060-10-00 Phase II 1 country Medica Scientia Innovation Research S.L.
An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive … Ended

2024-515301-26-00 Phase II 1 country Ospedale San Raffaele S.r.l.
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended

2024-513870-23-00 Phase III 8 countries Gilead Sciences Inc.
Study of Sacituzumab Govitecan’s Long-Term Safety in Subjects with Metastatic Solid Tumors Ended

2023-505336-34-00 Phase IV 3 countries Gilead Sciences Inc.
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN… Ended

2025-521489-80-00 Phase II 1 country Medica Scientia Innovation Research S.L.

Showing 25–32 of 32 trials

← All drugs A–Z